Biotech Values

[DewDiligence]

DNDN—without more data it is impossible to disentangle the root cause - all risk issue, all cash flow, or all end-user demand?

DNDN has already signaled that end-user demand is the problem—or at least a major part of the problem—and that’s why the share price is off ~70%. No biotech company lays off manufacturing staff to resolve a temporary issue with reimbursement, cash flow, or cash density.